Tucidinostat
Angioimmunoblastic T-Cell Lymphoma
Explore 52 assets in Angioimmunoblastic T-Cell Lymphoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07168317CT.gov Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL | — | Recruiting | — | — | — |
NCT07058103CT.gov Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL | — | Recruiting | — | — | — |
NCT05572983CT.gov Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | — | Recruiting | — | — | — |
NCT05179213CT.gov Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | — | Unknown | — | — | — |
NCT04831710CT.gov Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | — | Unknown | — | — | — |
NCT03853044CT.gov Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | — | Unknown | — | — | — |
NCT03273452CT.gov Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Angioimmunoblastic T-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucidinostat (this asset) | The Affiliated Hospital of Xuzhou Medical University | P2 | CCC · 53 |
| Isocyclophosphamide | Shandong Provincial Hospital | P4 | BBB |
| Dexasone | Ou Bai, MD/PHD | P2 | BB |
| Azacitidine | National Cancer Institute (NCI) | P4 | BB |
| Romidepsin | The Lymphoma Academic Research Organisation | P3 | BB |
| Prednisone | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Etoposide | Eric Jacobsen, MD | P4 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BB |
| Adriamycin | City of Hope Medical Center | P4 | BB |
+42 more in the Angioimmunoblastic T-Cell Lymphoma cohort
Other indications for Tucidinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 69 |
| Acute Lymphoblastic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucidinostat in Angioimmunoblastic T-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucidinostat-angioimmunoblastic-t-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →